Literature DB >> 31362988

Regulation of PLPP3 gene expression by NF-κB family transcription factors.

Guogen Mao1,2, Susan S Smyth1,2, Andrew J Morris3,2.   

Abstract

Lipid phosphate phosphatase 3 (LPP3), encoded by the PLPP3 gene, is an integral membrane enzyme that dephosphorylates phosphate esters of glycero- and sphingophospholipids. Cell surface LPP3 can terminate the signaling actions of bioactive lysophosphatidic acid (LPA) and sphingosine 1 phosphate, which likely explains its role in developmental angiogenesis, vascular injury responses, and cell migration. Heritable variants in the final intron PLPP3 associate with interindividual variability in coronary artery disease risk that may result from disruption of enhancer sequences that normally act in cis to increase expression of the gene. However, the mechanisms regulating PLPP3 expression are not well understood. We show that the human PLPP3 promoter contains three functional NF-κB response elements. All of these are required for maximal induction of PLPP3 promoter activity in reporter assays. The identified sequences recruit RelA and RelB components of the NF-κB transcription complex to chromatin, and these transcription factors bind to the identified target sequences in two different cell types. LPA promotes binding of Rel family transcription factors to the PLPP3 promoter and increases PLPP3 gene expression through mechanisms that are attenuated by an NF-κB inhibitor, LPA receptor antagonists, and inhibitors of phosphoinositide 3 kinase. These findings indicate that up-regulation of PLPP3 during inflammation and atherosclerosis results from canonical activation of the NF-κB signaling cascade to increase PLPP3 expression through nuclear import and binding of RelA and RelB transcription factors to the PLPP3 promoter and suggest a mechanism by which the LPP3 substrate, LPA, can regulate PLPP3 expression.

Entities:  

Keywords:  glycerophospholipid; glycerosphingolipid; lysophospholipid; phosphatase; transcription promoter

Mesh:

Substances:

Year:  2019        PMID: 31362988      PMCID: PMC6755815          DOI: 10.1074/jbc.RA119.009002

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

Review 1.  Introduction to NF-kappaB: players, pathways, perspectives.

Authors:  T D Gilmore
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

2.  Dual role for phosphoinositides in regulation of yeast and mammalian phospholipase D enzymes.

Authors:  Vicki A Sciorra; Simon A Rudge; Jiyao Wang; Stuart McLaughlin; JoAnne Engebrecht; Andrew J Morris
Journal:  J Cell Biol       Date:  2002-12-16       Impact factor: 10.539

Review 3.  AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation.

Authors:  T O Chan; S E Rittenhouse; P N Tsichlis
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

Review 4.  Integral membrane lipid phosphatases/phosphotransferases: common structure and diverse functions.

Authors:  Yury J Sigal; Mark I McDermott; Andrew J Morris
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

Review 5.  Nuclear factor kappaB signaling in atherogenesis.

Authors:  Menno P J de Winther; Edwin Kanters; Georg Kraal; Marten H Hofker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-24       Impact factor: 8.311

6.  Sequential actions of phospholipase D and phosphatidic acid phosphohydrolase 2b generate diglyceride in mammalian cells.

Authors:  V A Sciorra; A J Morris
Journal:  Mol Biol Cell       Date:  1999-11       Impact factor: 4.138

Review 7.  Co-ordinate regulation of growth factor receptors and lipid phosphate phosphatase-1 controls cell activation by exogenous lysophosphatidate.

Authors:  C Pilquil; Z C Ling; I Singh; K Buri; Q X Zhang; D N Brindley
Journal:  Biochem Soc Trans       Date:  2001-11       Impact factor: 5.407

8.  The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.

Authors:  Janos L Tanyi; Andrew J Morris; Judith K Wolf; Xianjun Fang; Yutaka Hasegawa; Ruth Lapushin; Nelly Auersperg; Yury J Sigal; Robert A Newman; Edward A Felix; Edward N Atkinson; Gordon B Mills
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

9.  Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.

Authors:  Hideo Ohta; Koichi Sato; Naoya Murata; Alatangaole Damirin; Enkhzol Malchinkhuu; Junko Kon; Takao Kimura; Masayuki Tobo; Yuji Yamazaki; Tomoko Watanabe; Mikio Yagi; Motoko Sato; Rika Suzuki; Hideko Murooka; Teruyuki Sakai; Tsuyoshi Nishitoba; Dong-Soon Im; Hiromi Nochi; Koichi Tamoto; Hideaki Tomura; Fumikazu Okajima
Journal:  Mol Pharmacol       Date:  2003-10       Impact factor: 4.436

10.  The lipid phosphatase LPP3 regulates extra-embryonic vasculogenesis and axis patterning.

Authors:  Diana Escalante-Alcalde; Lidia Hernandez; Hervé Le Stunff; Ryu Maeda; Hyun-Shik Lee; Vicki A Sciorra; Ira Daar; Sarah Spiegel; Andrew J Morris; Colin L Stewart
Journal:  Development       Date:  2003-10       Impact factor: 6.868

View more
  8 in total

1.  Effects of diet and hyperlipidemia on levels and distribution of circulating lysophosphatidic acid.

Authors:  Maria P Kraemer; Guogen Mao; Courtney Hammill; Baoxiang Yan; Yu Li; Fredrick Onono; Susan S Smyth; Andrew J Morris
Journal:  J Lipid Res       Date:  2019-09-04       Impact factor: 5.922

2.  Bioactive lipids and metabolic syndrome-a symposium report.

Authors:  Loren M DeVito; Edward A Dennis; Barbara B Kahn; Gerald I Shulman; Joseph L Witztum; Sudeshna Sadhu; Joseph Nickels; Matthew Spite; Susan Smyth; Sarah Spiegel
Journal:  Ann N Y Acad Sci       Date:  2022-02-25       Impact factor: 6.499

Review 3.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

4.  Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway.

Authors:  Xuejiao Liu; Yiming Tu; Yifeng Wang; Di Zhou; Yulong Chong; Lin Shi; Guanzheng Liu; Xu Zhang; Sijin Wu; Huan Li; Shangfeng Gao; Mingshan Niu; Rutong Yu
Journal:  Cancer Cell Int       Date:  2020-03-30       Impact factor: 5.722

Review 5.  Lipid Phosphate Phosphatases and Cancer.

Authors:  Xiaoyun Tang; David N Brindley
Journal:  Biomolecules       Date:  2020-09-02

6.  Lipid phosphate phosphatase 3 in smooth muscle cells regulates angiotensin II-induced abdominal aortic aneurysm formation.

Authors:  Patrick M Van Hoose; Liping Yang; Maria Kraemer; Margo Ubele; Andrew J Morris; Susan S Smyth
Journal:  Sci Rep       Date:  2022-04-05       Impact factor: 4.379

7.  Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast.

Authors:  Vincent Geldhof; Laura P M H de Rooij; Liliana Sokol; Jacob Amersfoort; Maxim De Schepper; Katerina Rohlenova; Griet Hoste; Adriaan Vanderstichele; Anne-Marie Delsupehe; Edoardo Isnaldi; Naima Dai; Federico Taverna; Shawez Khan; Anh-Co K Truong; Laure-Anne Teuwen; François Richard; Lucas Treps; Ann Smeets; Ines Nevelsteen; Birgit Weynand; Stefan Vinckier; Luc Schoonjans; Joanna Kalucka; Christine Desmedt; Patrick Neven; Massimiliano Mazzone; Giuseppe Floris; Kevin Punie; Mieke Dewerchin; Guy Eelen; Hans Wildiers; Xuri Li; Yonglun Luo; Peter Carmeliet
Journal:  Nat Commun       Date:  2022-09-20       Impact factor: 17.694

Review 8.  Study on the Correlation Between NF-κB and Central Fatigue.

Authors:  Xingzhe Yang; Feng Li; Yan Liu; Danxi Li; Jie Li
Journal:  J Mol Neurosci       Date:  2021-02-14       Impact factor: 3.444

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.